{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T15:35:01Z","timestamp":1649086501164},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/ncc.0b013e3182642d98","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T16:54:07Z","timestamp":1356022447000},"page":"198-205","source":"Crossref","is-referenced-by-count":2,"title":["Implementing an Evidence-Based Risk Assessment Tool to Predict Chemotherapy-Induced Neutropenia in Women With Breast Cancer"],"prefix":"10.1097","volume":"36","author":[{"given":"Li-Lu","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Chin","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Fang","family":"Horng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/sj.bjc.6605271","article-title":"Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review.","volume":"101","author":"Trueman","year":"2009","journal-title":"Brit J Cancer"},{"issue":"7","key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1200\/JCO.1998.16.7.2392","article-title":"First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.","volume":"16","author":"Silber","year":"1998","journal-title":"J Clin Oncol"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM198101013040103","article-title":"Dose-response effect of adjuvant chemotherapy in breast cancer.","volume":"304","author":"Bonadonna","year":"1981","journal-title":"N Engl J Med"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.","volume":"90","author":"Budman","year":"1998","journal-title":"J Natl Cancer I"},{"issue":"suppl 1","key":"R7-4-20210203","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0959-8049(99)00259-2","article-title":"Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer.","volume":"36","author":"Chang","year":"2000","journal-title":"Eur J Cancer"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","article-title":"Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.","volume":"8","author":"Kwak","year":"1990","journal-title":"J Clin Oncol"},{"key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.annonc.a058619","article-title":"Prognostic significance of received relative dose intensity in non-Hodgkins lymphoma patients: application to LNH-87 protocol. The GELA (Groupe dEtude des Lymphomes de lAdulte).","volume":"4","author":"Lepage","year":"1993","journal-title":"Ann Oncol"},{"issue":"6","key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia.","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4","article-title":"Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.","volume":"91","author":"Mayers","year":"2001","journal-title":"Cancer"},{"issue":"8","key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.12-8-1019","article-title":"Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.","volume":"12","author":"Courtney","year":"2007","journal-title":"Oncologist"},{"issue":"1","key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","article-title":"Epidemiology of febrile neutropenia.","volume":"1","author":"Lyman","year":"2003","journal-title":"Support Cancer Ther"},{"issue":"2","key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1992.10.2.316","article-title":"Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.","volume":"10","author":"Talcott","year":"1992","journal-title":"J Clin Oncol"},{"issue":"2","key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1188\/07.ONF.403-409","article-title":"Assessment of neutropenia-related quality of life in a clinical setting.","volume":"34","author":"Ropka","year":"2007","journal-title":"Oncol Nurs Forum"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"European Organization for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors.","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"R23-4-20210203","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/annonc\/mdn655","article-title":"A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies.","volume":"20","author":"Moreau","year":"2009","journal-title":"Ann Oncol"},{"issue":"12","key":"R25-4-20210203","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1080\/1042819031000119262","article-title":"Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkins lymphoma receiving CHOP chemotherapy.","volume":"44","author":"Lyman","year":"2003","journal-title":"Leukemia Lymphoma"},{"issue":"4","key":"R26-4-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/CCO.0b013e3281a3c0ba","article-title":"Granulocyte colony-stimulating factors: finding the right indication.","volume":"19","author":"Lyman","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"R27-4-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1191\/1078155201jp084oa","article-title":"Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature.","volume":"7","author":"Wilson-Royalty","year":"2001","journal-title":"J Oncol Pharm Pract"},{"key":"R29-4-20210203","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2354.2009.01121.x","article-title":"Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumors.","volume":"19","author":"Lopez-Pousa","year":"2010","journal-title":"Eur J Cancer Care"},{"issue":"15","key":"R30-4-20210203","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jama.282.15.1453","article-title":"Evaluation of conflict of interest in economic analyses of new drugs used in oncology.","volume":"282","author":"Friedberg","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"R32-4-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00520-003-0442-z","article-title":"Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors.","volume":"11","author":"Savvides","year":"2003","journal-title":"Support Cancer Care"},{"issue":"6","key":"R34-4-20210203","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1287\/mnsc.1060.0692","article-title":"Implementing new practices: an empirical study of organizational learning in hospital intensive care units.","volume":"53","author":"Tucker","year":"2007","journal-title":"Manage Sci"},{"key":"R35-4-20210203","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1188\/06.ONF.347-352","article-title":"Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.","volume":"33","author":"Donohue","year":"2006","journal-title":"Oncol Nurs Forum"},{"key":"R36-4-20210203","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1548-5315(11)70747-1","article-title":"Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia: from paper to clinical practice.","volume":"3","author":"Maxwell","year":"2006","journal-title":"Community Oncology"},{"key":"R37-4-20210203","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00002820-200501000-00009","article-title":"Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices.","volume":"28","author":"White","year":"2005","journal-title":"Cancer Nurs"},{"issue":"2","key":"R38-4-20210203","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1188\/07.ONF.347-353","article-title":"Nurses guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors.","volume":"34","author":"Wilson","year":"2007","journal-title":"Oncol Nurs Forum"}],"container-title":["Cancer Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/NCC.0b013e3182642d98","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:57:06Z","timestamp":1620964626000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002820-201305000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ncc.0b013e3182642d98","relation":{},"ISSN":["0162-220X"],"issn-type":[{"value":"0162-220X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}